v3.26.3
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Information [Line Items]            
Revenues, net $ 35,121   $ 1,571   $ 36,563 $ 3,741
Less:            
Cost of revenues 3,347   111   3,631 265
Research and development expenses 145,747   164,568   347,763 317,487
Share-based compensation         162,639 163,999
Gain on litigation settlement 0   0   (392) 0
Change in fair value of investments (60,292)   (128,501)   (96,929) (109,376)
Change in fair value of liability instruments 0   20,959   0 23,288
Interest income (41,612)   (45,341)   (78,534) (93,663)
Other expense, net 200   5,694   2,330 16,902
Income tax (benefit) expense (13,371)   6,995   (17,329) 11,644
Income from discontinued operations, net of tax (15,763)   0   (15,763) 0
Net loss (137,211) $ (290,606) (166,039) $ (273,911) (427,817) (439,950)
Product revenue, net            
Segment Information [Line Items]            
Revenues, net 30,969   0   30,969 0
License, milestone and other revenue            
Segment Information [Line Items]            
Revenues, net 4,152   1,571   5,594 3,741
Reportable Segment            
Less:            
Cost of revenues 3,347   111   3,631 265
Other research and development expenses 7,698   9,684   15,557 19,321
Other selling, general and administrative expenses 43,952   34,349   78,658 67,179
Gain on litigation settlement 0   0   (392) 0
Change in fair value of investments (60,292)   (128,501)   (96,929) (109,376)
Change in fair value of liability instruments 0   20,959   0 23,288
Interest income (41,612)   (45,341)   (78,534) (93,663)
Other expense, net 200   5,694   2,330 16,902
Income tax (benefit) expense (13,371)   6,995   (17,329) 11,644
Net loss (137,211)   (166,039)   (427,817) (439,950)
Reportable Segment | Product revenue, net            
Segment Information [Line Items]            
Revenues, net 30,969   0   30,969 0
Reportable Segment | License, milestone and other revenue            
Segment Information [Line Items]            
Revenues, net 4,152   1,571   5,594 3,741
Reportable Segment | Anti-FcRn franchise—endocrine diseases            
Less:            
Research and development expenses 22,461   24,895   65,346 44,224
Reportable Segment | Anti-FcRn franchise—neurological diseases            
Less:            
Research and development expenses 18,274   23,087   43,729 44,024
Reportable Segment | Anti-FcRn franchise—rheumatology diseases            
Less:            
Research and development expenses 9,864   13,611   32,204 21,820
Reportable Segment | Anti-FcRn franchise—dermatology diseases            
Less:            
Research and development expenses 648   7,952   8,190 13,097
Reportable Segment | Anti-FcRn franchise—other clinical and nonclinical            
Less:            
Research and development expenses 268   319   2,877 2,711
Reportable Segment | Brepocitinib            
Less:            
Research and development expenses 14,436   14,715   28,528 29,735
Reportable Segment | Mosliciguat            
Less:            
Research and development expenses 19,051   7,467   32,092 15,852
Reportable Segment | Other development and discovery programs            
Less:            
Research and development expenses 11,815   11,184   22,933 21,420
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense            
Less:            
Share-based compensation 7,965   10,996   16,686 22,095
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment            
Less:            
Share-based compensation 7,965   10,996   16,686 22,095
Personnel-related expenses 33,267   40,658   79,621 83,188
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense            
Less:            
Share-based compensation 71,332   70,825   145,953 141,904
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Reportable Segment            
Less:            
Share-based compensation 71,332   70,825   145,953 141,904
Personnel-related expenses $ 38,792   $ 37,951   $ 94,992 $ 68,061